Ajinomoto, Albireo sign licensing agreement for elobixibat
Under the agreement, Ajinomoto gains exclusive rights to elobixibat and in return the company will pay pay a significant upfront fee, milestones and tiered double-digit royalties to Albireo.
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
AggregateSpend360 will support local, country-specific and global transparency and reporting requirements. The service, available in Software as a Service (SaaS) and licensed models, collects all necessary compliance data